Thursday September 24, 2020

Major share buyback by Trinity Biotech after FDA sinks cardiac test

Company says it has around $85 million of cash in the bank

Ian Guider

Markets Editor

@ianguider
30th October, 2016
Trinity Biotech head offices

Trinity Biotech, the Bray-based maker of medical diagnostic equipment, plans to “aggressively” buy back its stock in a bid to lift its share price, which collapsed this month after it failed to secure regulatory approval for a new test for heart attacks.

The company said last week that it had about $85 million of cash in the bank and while it had looked at a number of potential acquisitions to boost its growth,...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Related Stories

The way we did business a few months ago may never return – so the opportunity is to make changes that will both aid recovery and set us up well for our new futures

Tom Maguire | 4 months ago

What’s coming up today and what you might have missed

Hannah O’Brien | 9 months ago